Riskpilot← Back to searchSign inGet full accessAvimab AB
ABActiveOrg 5568384332Tvistevägen 48 CResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20110 employees
Revenue 2024
SEK 0
EBITDA margin
—
+200% vs 2023
Equity ratio
88.3%
Financial strength
Net profit 2024
SEK 40K
+186% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK 51K | +200% |
| Net profit | SEK 40K | +186% |
| Total assets | SEK 103K | +16% |
| Equity | SEK 91K | +20% |
| Employees | 0 | — |
Legal name
Avimab AB
Org number
5568384332
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
15 januari 2011
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Olofsson, Per Anders Thomas
Company purpose
Föremålet för bolagets verksamhet är utveckling och produktion inom området bioteknik, medicin, medicinsk teknik, biokemi och cellbiologi, exploatering av patent och uppfinningar samt äga och förvalta värdepapper och annan därmed förenlig verksamhet.
Address
Tvistevägen 48 C
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −3 | 201 | 227 | 114 | 105 | 134 | 72 | 140 | 17 | 51 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −3 | 201 | 227 | 114 | 105 | 134 | 72 | 140 | 17 | 51 |
| Net financials | — | — | — | — | — | — | — | — | — | — |
| Profit before tax | −3 | 154 | 171 | 160 | 162 | 135 | 72 | 140 | 18 | 50 |
| Tax | −0 | −31 | −38 | −35 | −35 | −29 | −15 | −29 | −4 | −10 |
| Net profit | −3 | 123 | 133 | 125 | 127 | 106 | 57 | 111 | 14 | 40 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 37 | 238 | 401 | 304 | 201 | 197 | 113 | 195 | 89 | 103 |
| Equity | 36 | 159 | 192 | 192 | 194 | 174 | 112 | 163 | 76 | 91 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 | 32 | 106 | 55 | 7 | 22 | 2 | 32 | 12 | 12 |
| Total debt | 1 | 32 | 106 | 55 | 7 | 22 | 2 | 32 | 12 | 12 |
EBITDA margin
5100000.0%
This company
15.8%
Market median
+32278381% vs market
20152024
Equity ratio
88.3%
This company
38.2%
Market median
+131% vs market
20152024
Return on equity
44.0%
This company
18.4%
Market median
+139% vs market
20152024
Net profit margin
4000000.0%
This company
8.1%
Market median
+49382616% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
0.13×
This company
0.62×
Market median
+79% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Avimab AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ulf Johan Greger Nordlund | Board of Directors | 0 companies |
| Kjell Lennart Kristoffer Brännström | Board of Directors | 0 companies |
| Monika Kristina Vestling | Board of Directors | 0 companies |
| Per Anders Thomas Olofsson | Chairman | 0 companies |
| Malin Kristina Walfridsson | Board of Directors | 0 companies |